A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health
Igor Goryanin, Bob Damms, Irina Goryanin · 2026
Read A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health by Igor Goryanin, Bob Damms, Irina Goryanin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13454951.txt.
Description
Goryanin and colleagues present a computer model of aging in 2026 that treats aging itself as an outcome drugs can change. Their model joins four parts. It tracks drug action on body chemistry, side effects, and damage and repair states tied to frailty. It also tracks blood markers of metabolic health, meaning how the body handles sugar and fat. The drugs are semaglutide, SGLT2 inhibitors, metformin, and rapamycin.
The team tuned the semaglutide part against STEP trial results, matching weight loss, blood sugar gains, and nausea within limits. Wider tests showed strong metabolic effects for semaglutide but almost none on blood sugar for rapamycin. Simulations found two best mixes. One joined a GLP-1 drug, an SGLT2 inhibitor, and metformin for metabolic gain. The other added rapamycin to that base for aging related gain. The two goals, the authors stress, do not point to the same treatment.
Catalog record
| CREATOR | Igor Goryanin, Bob Damms, Irina Goryanin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |